Drugs for Chronic Asthma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 54)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Hormones |
|
Phase 4 |
|
|
|
2 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
3 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
4 |
|
Leukotriene Antagonists |
|
Phase 4 |
|
|
|
5 |
|
Platelet Aggregation Inhibitors |
|
Phase 4 |
|
|
|
6 |
|
Prasugrel hydrochloride |
|
Phase 4 |
|
389574-19-0 |
|
7 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
8 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
9 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
10 |
|
Analgesics |
|
Phase 4 |
|
|
|
11 |
|
Insulin glargine |
Approved |
Phase 3 |
|
160337-95-1 |
|
Synonyms:
Insulin glargine
Insulin glargine (rDNA origin)
|
Insulin glargine recombinant
Insulina glargina
|
|
12 |
|
Zinc |
Approved, Investigational |
Phase 3 |
|
7440-66-6 |
32051 |
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
|
Mannosidase b, alpha
Neutral alpha mannosidase
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
13 |
|
Atorvastatin |
Approved |
Phase 2, Phase 3 |
|
134523-00-5 |
60823 |
Synonyms:
(3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid
(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
(3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
(betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
134523-00-5
134523-03-8
7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID
7-[2-(4-FLUORO-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoate
7-[2-(4-FLUORO-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoIC ACID
AC-15611
AC1L1TZT
AC1Q1OZQ
AKOS000281127
Anhydrous, atorvastatin calcium
Atogal
Atorlip
Atorpic
atorvastatin
Atorvastatin
Atorvastatin (INN)
Atorvastatin [INN:BAN]
Atorvastatin acid
Atorvastatin calcium
Atorvastatin calcium anhydrous
Atorvastatin calcium hydrate
Atorvastatin calcium trihydrate
Atorvastatin, calcium salt
atorvastatina
Atorvastatina
atorvastatine
Atorvastatine
atorvastatinium
atorvastatinum
Atorvastatinum
atrovastin
BIDD:GT0336
C06834
C33H35FN2O5
|
Calcium anhydrous, atorvastatin
Calcium hydrate, atorvastatin
Calcium salt atorvastatin
Calcium trihydrate, atorvastatin
Calcium, atorvastatin
Cardyl
CCRIS 7159
CHEBI:39548
CHEMBL1487
CI 981
CID60823
D07474
DB01076
Faboxim
Hipolixan
HSDB 7039
Hydrate, atorvastatin calcium
Lipitor
Lipitor (TN)
Lipitor(TM)
Lipotropic
Lipovastatinklonal
Liprimar
Liptonorm
Lowden
LS-136975
MolPort-000-883-773
NCGC00159458-02
nchembio.301-comp8
Normalip
Sincol
Sortis
Sortis (TN)
Sotis
Torvacard
Torvast
Totalip
Tozalip
Trihydrate, atorvastatin calcium
Tulip
UNII-A0JWA85V8F
Vastina
Xanator
Xarator
Xavator
Zurinel
|
|
14 |
|
Nedocromil |
Approved, Investigational |
Phase 3 |
|
69049-73-6 |
50294 |
Synonyms:
9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)chinolin-2,8-dicarbonsaeure
9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)chinolin-2,8-dicarbonsäure
9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylate
9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid
9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid
Allergan brand OF nedocromil sodium
Alocril
ASTA medica brand OF nedocromil sodium
Aventis behring brand OF nedocromil sodium
Aventis brand OF nedocromil sodium
Brionil
Calcium, nedocromil
Cetimil
Fisons brand OF nedocromil sodium
Halamid
Irtan
Lesvi brand OF nedocromil sodium
Nedocromil
Nédocromil
|
Nedocromil [USAN:BAN:INN]
Nedocromil calcium
Nedocromil sodium
Nedocromil, calcium salt (1:1)
Nedocromil, disodium salt
Nedocromil, disodium salt, hydrate
Nedocromilo
Nedocromilo [Spanish]
Nedocromilum
Nedocromilum [Latin]
Pantheon brand OF nedocromil sodium
Rapitil
Rhône-poulenc rorer brand OF nedocromil sodium
Sodium, nedocromil
Tilad
Tilade
Tilaire
Tilavist
Vita brand OF nedocromil sodium
|
|
15 |
|
Levoleucovorin |
Approved, Investigational |
Phase 3 |
|
68538-85-2 |
149436 |
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-5-Formyltetrahydrofolate
(6S)-5-formyltetrahydrofolic acid
(6S)-5-Formyltetrahydrofolic acid
(6S)-Folinate
(6S)-Folinic acid
(6S)-Leucovorin
(S)-Leucovorin
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
6 S Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
ácido levofolínico
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid SF
Folinic acid-SF
Fusilev
Kunyrin
Leucoverin
|
Leucovorin
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leukovorin
Leukovorum
Levo leucovorin
Levofolene
Levofolinate
Levofolinic acid
Levoleucovorin
Levo-leucovorin
L-Folinate
L-Folinic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
16 |
|
Omalizumab |
Approved, Investigational |
Phase 3 |
|
242138-07-4 |
|
Synonyms:
242138-07-4
D05251
Omalizumab
Omalizumab (genetical recombination)
|
Omalizumab (genetical recombination) (JAN)
Omalizumab (USAN/INN)
Xolair
Xolair (TN)
|
|
17 |
|
Methotrexate |
Approved |
Phase 3 |
|
1959-05-2, 59-05-2 |
126941 |
Synonyms:
4-Amino-10-methylfolate
4-amino-10-methylfolic acid
4-Amino-10-methylfolic acid
4-Amino-N(10)-methylpteroylglutamate
4-amino-N(10)-methylpteroylglutamic acid
4-Amino-N(10)-methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Dicesium salt methotrexate
Emtexate
Emtexic acid
Folex
HDMTX
Hydrate, methotrexate
L-Amethopterin
Ledertrexate
Ledertrexic acid
Metatrexan
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate
|
Méthotrexate
Methotrexate hydrate
Methotrexate sodium
Methotrexate Sodium
Methotrexate, (D)-isomer
Methotrexate, (DL)-isomer
Methotrexate, dicesium salt
Methotrexate, disodium salt
Methotrexate, sodium salt
Methotrexatum
Methotrexic acid
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
MTX
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamate
N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-Bismethylpteroylglutamic acid
N-Bismethylpteroylglutamic Acid
Otrexup
Rheumatrex
Sodium, methotrexate
Trexall
Xatmep
|
|
18 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
ácido fólico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
AI3-26387
AKOS000503224
Antianemia factor
Apo-Folic
ARONIS014410
b9, Vitamin
BIDD:ER0563
BIDD:GT0641
BIF0608
bmse000299
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat b activ
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
Facid
Factor U
FOL
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
folic acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
|
Folipac
Folsaeure
Folsan
Folsaure
Folsäure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
Incafolic
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
Liver lactobacillus casei factor
Liver Lactobacillus casei factor
LS-2157
Millafol
Mission prenatal
Mittafol
MLS001304016
MLS001335861
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
nchembio.108-comp10
Nifolin
Nifolin [Denmark]
NINDS_000494
Novofolacid
Novofolacid [Canada]
N-Pteroyl-L-glutamate
N-pteroyl-L-glutamic acid
N-Pteroyl-L-glutamic acid
NSC 3073
PGA
PGA (VAN)
Prestwick_230
Prestwick3_000627
PteGlu
Pteroylglutamate
Pteroylglutamic acid
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
Serum Folate Level
SMP2_000137
SMR000471860
SPBio_001357
Spectrum_001381
SPECTRUM1502020
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin b9
Vitamin B9
Vitamin Bc
Vitamin BC
Vitamin be
Vitamin Be
Vitamin m
Vitamin M
|
|
19 |
|
Beclomethasone |
|
Phase 3 |
|
4419-39-0 |
20469 |
Synonyms:
(11beta,16beta)-9-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
(8R,9S,10S,11S,13R,14R,16R,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
(8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
4419-39-0
9alpha-Chloro-11beta,17alpha,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione
9alpha-Chloro-16beta-methyl-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione
9alpha-Chloro-16beta-methylprednisolone
9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
9-Chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione
AC1L1DDX
AC1L2GBM
AC1O7G0A
Anceron
B 0385
B0385_SIGMA
BCBcMAP01_000159
Beclocort
Beclometason
Beclometason (TN)
Beclometasona
Beclometasona [INN-Spanish]
Beclometasondipropionat Mikron
Beclometasone (INN)
Beclometasone [INN]
Beclometasonum
Beclometasonum [INN-Latin]
beclomethasone
Becloval
Becodisks
Beconasol
Becotide
BIDD:GT0556
BMJ 5800
C06842
C22H29ClO5
CHEBI:3001
CHEMBL1586
|
CID11407187
CID11957468
CID20469
CID2308
CID6603734
CPD000466920
D07495
DB00394
EINECS 224-585-9
EU-0100159
HMS2052E17
Inalone
Lopac0_000159
Lopac-B-0385
LS-174992
MLS000028668
MLS001076089
MLS001333211
MLS001333212
MLS001424231
MLS002153387
MolPort-003-844-701
MolPort-003-940-375
NCGC00015136-01
NCGC00015136-02
NCGC00093647-01
NCGC00162078-01
NCGC00162078-02
NCGC00164402-01
SAM001246898
SMP1_000039
SMR000058899
SMR000466920
UNII-KGZ1SLC28Z
Vancenase AQ
Viarex
ZINC04097285
|
|
20 |
|
Insulin, Globin Zinc |
|
Phase 3 |
|
|
|
21 |
|
Hypoglycemic Agents |
|
Phase 3 |
|
|
|
22 |
|
Insulin, Short-Acting |
|
Phase 3 |
|
|
|
23 |
|
Insulin, Isophane |
|
Phase 3 |
|
|
|
24 |
|
Isophane Insulin, Human |
|
Phase 3 |
|
|
|
25 |
|
insulin |
|
Phase 3 |
|
|
|
26 |
|
Protamines |
|
Phase 3 |
|
|
|
27 |
|
Isophane insulin, beef |
|
Phase 3 |
|
|
|
28 |
|
Methacholine Chloride |
|
Phase 2, Phase 3 |
|
|
|
29 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
30 |
|
Hypolipidemic Agents |
|
Phase 2, Phase 3 |
|
|
|
31 |
|
Anticholesteremic Agents |
|
Phase 2, Phase 3 |
|
|
|
32 |
|
Lipid Regulating Agents |
|
Phase 2, Phase 3 |
|
|
|
33 |
|
Cromolyn Sodium |
|
Phase 3 |
|
|
|
34 |
|
Vitamin B Complex |
|
Phase 3 |
|
|
|
35 |
|
Immunosuppressive Agents |
|
Phase 3 |
|
|
|
36 |
|
Folic Acid Antagonists |
|
Phase 3 |
|
|
|
37 |
|
Vitamin B9 |
|
Phase 3 |
|
|
|
38 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
39 |
|
Antimetabolites |
|
Phase 3 |
|
|
|
40 |
|
Folate |
|
Phase 3 |
|
|
|
41 |
|
mometasone furoate |
Approved, Investigational, Vet_approved |
Phase 2 |
|
83919-23-7 |
|
Synonyms:
|
Mometasone furoate anhydrous
|
|
42 |
|
Albuterol |
|
Phase 2 |
|
|
|
43 |
|
Adrenergic beta-Agonists |
|
Phase 2 |
|
|
|
44 |
|
Adrenergic Agonists |
|
Phase 2 |
|
|
|
45 |
|
Neurotransmitter Agents |
|
Phase 2 |
|
|
|
46 |
|
Tocolytic Agents |
|
Phase 2 |
|
|
|
47 |
|
Adrenergic Agents |
|
Phase 2 |
|
|
|
48 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
49 |
|
Phosphodiesterase 4 Inhibitors |
|
Phase 2 |
|
|
|
50 |
|
Procaterol |
Approved, Investigational |
Phase 1 |
|
72332-33-3 |
688561 |
Synonyms:
(R*,s*)-(+-)-8-hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone
(R*,S*)-(+-)-8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone
5-[1-hydroxy-2-(propan-2-ylamino)butyl]quinoline-2,8-diol
60443-17-6
62929-91-3 (mono-hydrochloride)
72332-33-3
8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone
8-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)butyl]-1H-quinolin-2-one
AC-13705
AC1L1J8G
AC1Q6I3X
AR-1J3938
BRD-A22684332-003-02-3
BSPBio_003239
CHEMBL160519
CI-888
CID4916
D08424
EINECS 276-590-0
Hydrochloride, procaterol
KBio3_002739
L023776
LS-142797
Meptin
Meptin (TN)
MolPort-005-934-511
Monohydrochloride, procaterol
NSC 308904
NSC308904
|
OPC-2009
Pro air
Pro-air
ProAir
Pro-Air
Procaterol
PROCATEROL
Procaterol (INN)
Procaterol [INN:BAN]
Procaterol hydrochloride
Procaterol monohydrochloride
Procaterol Monohydrochloride
Procaterol monohydrochloride, (r*,r*)-(-)-isomer
Procaterol monohydrochloride, (r*,r*)-(+)-isomer
Procaterol monohydrochloride, (r*,r*)-(+-)-isomer
Procaterol monohydrochloride, (r*,s*)-(-)-isomer
Procaterol monohydrochloride, (r*,s*)-(+)-isomer
Procaterol, (r*,r*)-(+-)-isomer
Procaterol, (r*,s*)-(-)-isomer
Procaterolo
Procaterolo [DCIT]
Procaterolum
Procaterolum [INN-Latin]
Procaterolum [Latin]
SPBio_001400
Spectrum2_001550
Spectrum3_001770
STK632659
|
|
Interventional clinical trials:
(show all 27)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
TEAM (Trial on Efficacy and Quality of Life Among Asthmatic Patient With Montelukast) |
Completed |
NCT03096327 |
Phase 4 |
Montelukast;Placebo |
2 |
The Effect of Prasugrel on Bronchial Hyperreactivity and on Markers of Inflammation in Patients With Chronic Asthma: a Pilot Randomised Controlled Trial (PRINA Study) |
Completed |
NCT01305369 |
Phase 4 |
Prasugrel |
3 |
A Single-Center, Open-Label, Single-Dose Evaluation of the Duration and Extent of Bronchodilation Following Administration of Zileuton CR 1200 mg in Subjects With Stable, Chronic Asthma |
Completed |
NCT01805687 |
Phase 4 |
Zileuton extended release |
4 |
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 2-Period, Parallel-Group Study to Assess the Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients |
Completed |
NCT00911547 |
Phase 3 |
montelukast sodium;beclomethasone;Placebo inhaler;placebo tablet |
5 |
A Multicenter, Randomized, Double-blind, Placebo-Controlled Parallel Group 8-week Study to Evaluate the Efficacy and Safety of Chewable Montelukast When Initiated at the Start of the School Year in Pediatric Patients With Chronic Asthma |
Completed |
NCT00461032 |
Phase 3 |
montelukast;Comparator: Placebo |
6 |
A Multicenter, Double-Blind, Randomized Study Investigating the Clinical Effect of Montelukast on Allergic Rhinitis in Patients With Seasonal Allergic Rhinitis and Chronic Asthma |
Completed |
NCT00092885 |
Phase 3 |
MK0476, montelukast sodium;Comparator: placebo |
7 |
A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients With Chronic Asthma Who Smoke Cigarettes |
Completed |
NCT00284856 |
Phase 3 |
montelukast sodium;Comparator: Placebo;Comparator: fluticasone;Comparator: Placebo |
8 |
A 24-Week, Double-Blind, Parallel Group, Placebo and Active Controlled Study to Investigate the Efficacy and Safety of Daily Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Chronic Asthma |
Completed |
NCT00163527 |
Phase 3 |
Roflumilast |
9 |
Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared With Subcutaneous Human Insulin in the Therapy of Adult Subjects With Type 1 or Type 2 Diabetes Mellitus and Chronic Asthma: A One-Year, Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial |
Completed |
NCT00139659 |
Phase 3 |
Inhaled Insulin;Subcutaneous Insulin |
10 |
Randomised Controlled Trial to Evaluate the Effect of Statins on Asthma Control of Patients With Chronic Asthma |
Completed |
NCT00126048 |
Phase 2, Phase 3 |
Atorvastatin;Placebo |
11 |
A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Clinical Effect of Oral MK0476 Vs Placebo During the Allergy Season in Patients With Seasonal Aeroallergen Sensitivity and Chronic Asthma Which is Also Active During Allergy Season |
Completed |
NCT00092144 |
Phase 3 |
MK0476, montelukast sodium / Duration of Treatment: 4 weeks;Comparator: placebo / Duration of Treatment: 4 weeks |
12 |
A Multicenter, Open-Label, Controlled, Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma |
Completed |
NCT00943397 |
Phase 3 |
montelukast sodium;Comparator: Usual Care |
13 |
A Multicenter, Double-Blind, Randomized, Parallel-Group Chronic Asthma Study Comparing Montelukast With Placebo in 2- to 5-Year-Old Patients |
Completed |
NCT00968201 |
Phase 3 |
montelukast sodium;Comparator: Placebo |
14 |
Low-dose Methotrexate for Change in Global Initiative for Asthma Step 5 Medications in Chronic Severe Asthma: a Randomized Controlled Trial |
Not yet recruiting |
NCT02124226 |
Phase 3 |
Methotrexate;Placebo |
15 |
A Phase III Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Prospectively Evaluate Efficacy of Montelukast in Patients Aged 6 Months to 5 Years With Chronic Asthma |
Withdrawn |
NCT00540839 |
Phase 3 |
Montelukast sodium;Placebo to montelukast;Fluticasone propionate;Placebo to fluticasone |
16 |
Randomized, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma |
Completed |
NCT00666679 |
Phase 2 |
Comparator: mometasone;Comparator: montelukast;Comparator: placebo (unspecified) |
17 |
A Multicenter, Randomized, Double-Blind, Crossover Study Comparing the Effect of MK0359 and Placebo in Adult Patients With Chronic Asthma |
Completed |
NCT00482898 |
Phase 2 |
MK0359 |
18 |
A Multicenter, Randomized, Double Blind, Crossover Study Comparing the Effect of MK0524 With Placebo and Concomitant Administration of MK0524 Plus Montelukast in Adult Patients With Chronic Asthma |
Completed |
NCT00783601 |
Phase 2 |
Comparator: MK0524 + placebo;Comparator: MK0524 + montelukast;Comparator: placebo + montelukast;Comparator: Placebo |
19 |
A Phase II, Randomised, Double Blind, Placebo Controlled, Seven Way Crossover Study to Assess the Effect of Single Doses of RPL554 Compared to Salbutamol and Placebo Administered by Nebuliser on Lung Function of Patients With Chronic Asthma |
Completed |
NCT02427165 |
Phase 2 |
RPL554;Salbutamol;Placebo |
20 |
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study of MK0633 in Adult Patients With Chronic Asthma |
Terminated |
NCT00404313 |
Phase 2 |
MK0633;Comparator: placebo |
21 |
A Phase Ib Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Bronchodilatory Effect of MK0476 in Patients With Chronic Asthma |
Completed |
NCT00739297 |
Phase 1 |
Comparator: montelukast;Comparator: placebo |
22 |
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate in Adults With Chronic Asthma |
Completed |
NCT02022761 |
Phase 1 |
Laninamivir octanoate |
23 |
Impact of a Pharmaceutical Care Intervention to Improve Adherence of Inhaled Medication in Asthma and COPD Patients |
Completed |
NCT02386722 |
|
|
24 |
Montelukast in Chronic Asthma: Non-interventional Study With Montelukast 10 mg |
Completed |
NCT00802789 |
|
|
25 |
Effects of Submaximal Regular Physical Exercise on Quality of Life, Symptomatic Control, and Bronchial and Systemic Inflammatory Markers in Patients With Persistent Asthma |
Recruiting |
NCT04395937 |
|
|
26 |
Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus: A Randomized, Controlled Trial |
Active, not recruiting |
NCT04075110 |
Early Phase 1 |
Montelukast 10mg |
27 |
Initiation of Chronic Asthma Care Regimens in the Pediatric Emergency Department |
Withdrawn |
NCT00388739 |
|
Intervention: Budesonide;Usual care: albuterol + systemic steroids |
|